Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2016 Mar 15;26(6):1571-1575. doi: 10.1016/j.bmcl.2016.02.009. Epub 2016 Feb 4.

Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.

Author information

1
College of Life Science and Bioengineering, Beijing University of Technology, Beijing 100124, China.
2
Guangzhou Institute of Biomedicine and Health, Chinese Academy of Science, Guangzhou 510530, China.
3
College of Life Science and Bioengineering, Beijing University of Technology, Beijing 100124, China. Electronic address: huliming@bjut.edu.cn.
4
Beijing Dalitai Pharmaceutical Technology Co. Ltd, Beijing 100176, China.

Abstract

A series of novel morpholin-3-one-fused quinazoline derivatives were designed, synthesized and evaluated as EGFR tyrosine kinase inhibitors. Nineteen compounds showed significant inhibitory activities against EGFR(wt) kinase (IC50<1 μM). Compound a8 demonstrated the most potent inhibitory activity toward EGFR(wt) (IC50=53.1 nM). Compound a7 and a8 showed excellent inhibitory activities against mutant EGFR(T790M/L858R) and strong antiproliferative activity against H358 and A549 cell lines. Finally, molecular docking studies were performed to predict the possible binding mode of the target compounds. It is believed that this work would be very useful for designing a new series of tyrosine kinase inhibitors targeting EGFR.

KEYWORDS:

Anti-cancer; EGFR inhibitors; Molecular docking; NSCLC; Quinazoline

PMID:
26879314
DOI:
10.1016/j.bmcl.2016.02.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center